Showing results (1-10 of 471) with videos related to
Sort By:
Pageof 48
Stroke|April 17, 2014
Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patientsGaia Sirimarco, Julien Labreuche, Eric Bruckert, et al.Stroke|November 9, 2017
Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels TrialPeter Ganz, Pierre Amarenco, Larry B Goldstein, et al.Stroke|October 11, 2008
Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialHenrik Sillesen, Pierre Amarenco, Michael G Hennerici, et al.European Neurology|June 24, 2025
Fourteen Biomarkers and Subsequent Disability in Patients with Stroke Recurrence: Results from the SPARCL TrialElena Meseguer, Peter Ganz, Weihang Bao, et al.Journal of the American College of Cardiology|March 21, 2020
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL TrialMichael Szarek, Pierre Amarenco, Alfred Callahan, et al.Stroke|July 12, 2008
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) StudyLarry B Goldstein, Pierre Amarenco, Marian Lamonte, et al.Expert Opinion on Pharmacotherapy|October 25, 2007
Atorvastatin in prevention of stroke and transient ischaemic attackPierre AmarencoCerebrovascular Diseases (Basel, Switzerland)|April 4, 2009
Underlying pathology of stroke of unknown cause (cryptogenic stroke)Pierre AmarencoBulletin De L'Academie Nationale De Medecine|April 3, 2003
[Management of cerebral ischemia in acute phase]Pierre AmarencoPageof 48